Clement Ho

University of British Columbia

关注

立即认领

关注

立即认领

基本信息

浏览量：2

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 9 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

时间

引用量

主题

期刊级别

合作者

合作机构

Upfront Versus Delayed Systemic Therapy in Patients with Oligometastatic Cancer Treated with SABR in the Phase 2 SABR-5 Trial

Sarah Baker, Linden Lechner,Mitchell Liu,Jee Suk Chang,Ella Mae Cruz-Lim, Ben Mou,Will Jiang,Alanah Bergman,Devin Schellenberg,Abraham Alexander,Tanya Berrang,Andrew Bang,Nick Chng,Quinn Matthews,Hannah Carolan,Fred Hsu,Stacey Miller,Siavash Atrchian,Elisa Chan,Clement Ho,Islam Mohamed,Angela Lin,Vicky Huang,Ante Mestrovic,Derek Hyde,Chad Lund,Howard Pai,Boris Valev,Shilo Lefresne,Gregory Arbour,Irene Yu,Scott Tyldesley, Rob A. Olson

International Journal of Radiation OncologyBiologyPhysics（2024）

引用1浏览0WOS引用

77 Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiotherapy for Oligometastatic Disease: A Secondary Analysis of the Phase II SABR-5 Trial

Aiden Kooyman,Jee Suk Chang,Mitchell Liu,Will Jiang,Alanah Bergman,Devin Schellenberg,Benjamin Mou,Abraham Alexander,Hannah Carolan,Fred Hsu,Stacy Miller,Siavash Atrchian,Elisa Chan,Clement Ho,Islam Mohamed,Angela Lin,Tanya Berrang,Andrew Bang,Nick Chng,Quinn Matthews

Radiotherapy and Oncology (2024): S36

引用0浏览0引用

Should Organs at Risk (oars) Be Prioritized over Target Volume Coverage in Stereotactic Ablative Radiotherapy (SABR) for Oligometastases? a Secondary Analysis of the Population-Based Phase II SABR-5 Trial

Reno Eufemon Cereno,Benjamin Mou,Sarah Baker,Nick Chng,Gregory Arbour,Alanah Bergman,Mitchell Liu,Devin Schellenberg,Quinn Matthews,Vicky Huang,Ante Mestrovic,Derek Hyde,Abraham Alexander,Hannah Carolan,Fred Hsu,Stacy Miller,Siavash Atrchian,Elisa Chan,Clement Ho,Islam Mohamed,Angela Lin,Tanya Berrang,Andrew Bang,Will Jiang,Chad Lund,Howard Pai,Boris Valev,Shilo Lefresne,Scott Tyldesley,Robert A. Olson

RADIOTHERAPY AND ONCOLOGY（2023）

引用11浏览0WOS引用

Stereotactic Ablative Radiotherapy for Oligo-Progressive Cancers: Results of the Randomized Phase II STOP Trial

Devin Schellenberg,Zsolt Gabos,Adele Duimering,Brock Debenham,Alysa Fairchild,Fleur Huang,Lindsay Rowe,Diane Severin,Meredith Giuliani,Andrea Bezjak,Benjamin Lok,Srinivas Raman,Peter Chung,Yizhou Zhao,Clement Ho,Michael Lock,Alexander Louie,Shilo Lefresne,Hannah Carolan,Mitchell Liu,Vivian Yau,Allison Ye,Rob Olson,Benjamin Mou,Islam Mohamed,David Petrik,Maryam Dosani,Howard Pai,Boris Valev,Stewart Gaede,Andrew Warner,David Palma

International Journal of Radiation OncologyBiologyPhysics（2023）

引用2浏览0WOS引用

Prospective Longitudinal Assessment of Quality of Life after Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-Based SABR-5 Phase II Trial

Ella Mae Cruz-Lim,Benjamin Mou,Sarah Baker,Gregory Arbour,Kelsey Stefanyk,Will Jiang,Mitchell Liu,Alanah Bergman,Devin Schellenberg,Abraham Alexander,Tanya Berrang,Andrew Bang,Nick Chng,Quinn Matthews,Hannah Carolan,Fred Hsu,Stacy Miller,Siavash Atrchian,Elisa Chan,Clement Ho,Islam Mohamed,Angela Lin,Vicky Huang,Ante Mestrovic,Derek Hyde,Chad Lund,Howard Pai,Boris Valev,Shilo Lefresne,Scott Tyldesley,Robert Olson

International Journal of Radiation OncologyBiologyPhysicsno. 2 (2023): e224-e225

引用0浏览0WOS引用

58 Should Organs at Risk (OARS) Be Prioritized over Target Volume Coverage in Stereotactic Ablative Radiotherapy (SABR) for Oligometastases? a Secondary Analysis of the Population-Based Phase II SABR-5 Trial

Radiotherapy and Oncology (2023): S28-S29

引用0浏览0引用

Treatment with Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients with Cancer

Robert Olson,Will Jiang,Mitchell Liu,Alanah Bergman,Devin Schellenberg,Benjamin Mou,Abraham Alexander,Hannah Carolan,Fred Hsu,Stacy Miller,Siavash Atrchian,Elisa Chan,Clement Ho,Islam Mohamed,Angela Lin,Tanya Berrang,Andrew Bang,Nick Chng,Quinn Matthews,Sarah Baker,Vicky Huang,Ante Mestrovic,Derek Hyde,Chad Lund,Howard Pai,Boris Valev,Shilo Lefresene,Scott Tyldesley

JAMA Oncology（2022）

引用17浏览0引用

Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial

JAMA Oncol（2022）

引用10浏览0WOS引用

POPULATION BASED PHASE II TRIAL OF STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) FOR UP TO FIVE OLIGOMETASTASES: PRELIMINARY RESULTS OF THE SABR-5 TRIAL

Robert Olson,Will Jiang,Mitchell Liu,Alanah Bergman,Devin Schellenberg,Benjamin Mou,Abraham Alexander,Hannah Carolan,Fred Hsu,Stacy Miller,Siavash Atrchian,Elisa Chan,Clement Ho,Islam Mohamed,Angela Lin,Tanya Berrang,Andrew Bang,Nick Chng,Quinn Matthews,Ante Mestrovic,Derek Hyde,Vicky Huang,Chad Lund,Howard Pai,Boris Valev,Shilo Lefresne,Scott Tyldesley

RADIOTHERAPY AND ONCOLOGY (2021): S4-S4

引用0浏览0引用

作者统计

#Papers: 9

#Citation: 41

H-Index: 3

G-Index: 5

Sociability: 4

Diversity: 1

Activity: 6

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn